---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000067"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-05-11T20:06:06+00:00"
generated_at: "2026-05-11T22:44:40.214186+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q1 revenue up 42% to $377M; new $1B buyback program

## Summary
- Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).
- GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).
- New $1B share repurchase program through 2028; at least $400M expected in 2026.
- Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.
- Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes.

## SEC filing metadata
- accession: 0001159036-26-000067
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-05-11T20:06:06+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/halo-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000067
- JSON: https://secwatch.observer/filing/0001159036-26-000067.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000067.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
  - Period: first quarter ended March 31, 2026
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 11, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.